Andrew M Lovering
Overview
Explore the profile of Andrew M Lovering including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pardos S, Hope W, Kotsaki A, Das S, Giamarellos-Bourboulis E, Kontopoulouk T, et al.
J Antimicrob Chemother
. 2024 Oct;
79(12):3303-3312.
PMID: 39412246
Background: The population pharmacokinetics/pharmacodynamics (PK/PD) of minocycline, rifampicin and linezolid in patients with complicated skin and soft tissue infections (cSSTIs) caused by MRSA are described. Methods: Samples were collected in...
2.
Rawson T, Wilson R, Moore L, MacGowan A, Lovering A, Bayliss M, et al.
Open Forum Infect Dis
. 2021 Dec;
8(12):ofab573.
PMID: 34934774
This healthy volunteer study aimed to explore phenoxymethylpenicillin (penicillin-V) pharmacokinetics (PK) to support the planning of large dosing studies in adults. Volunteers were dosed with penicillin-V at steady state. Total...
3.
Price B, Morley R, Bowling F, Lovering A, Dobson C
PLoS One
. 2020 Feb;
15(2):e0228704.
PMID: 32069293
Diabetic foot ulcers can become chronic and non-healing despite systemic antibiotic treatment. The penetration of systematically-administered antibiotics to the site of infection is uncertain, as is the effectiveness of such...
4.
Bayliss M, Kyriakides M, Rigdova K, Grier S, Lovering A, Noel A, et al.
J Antimicrob Chemother
. 2019 Nov;
74(12):3643-3645.
PMID: 31730157
No abstract available.
5.
de Kraker M, Sommer H, de Velde F, Gravestock I, Weiss E, McAleenan A, et al.
Clin Infect Dis
. 2018 Aug;
67(12):1922-1931.
PMID: 30107400
Innovations are urgently required for clinical development of antibacterials against multidrug-resistant organisms. Therefore, a European, public-private working group (STAT-Net; part of Combatting Bacterial Resistance in Europe [COMBACTE]), has reviewed and...
6.
Lim F, Lovering A, Currie A, Jenkins D
J Antimicrob Chemother
. 2017 May;
72(9):2677-2678.
PMID: 28541475
No abstract available.
7.
Armstrong M, Spencer R, Lovering A, Gheduzzi S, Miles A, Learmonth I
Hip Int
. 2017 Jan;
12(1):23-27.
PMID: 28124329
The in vitro antibiotic elution characteristics (including the effects of cement fracture) of the following cements were studied: 1) CMW 1 with gentamicin, 2) Palacos R with gentamicin, 3) Palacos...
8.
Price B, Lovering A, Bowling F, Dobson C
Antimicrob Agents Chemother
. 2016 Sep;
60(11):6880-6889.
PMID: 27620475
Diabetes has major implications for public health, with diabetic foot ulcers (DFUs) being responsible for significant morbidity and mortality. A key factor in the development of nonhealing ulcers is infection,...
9.
Hay A, Redmond N, Turnbull S, Christensen H, Thornton H, Little P, et al.
Lancet Respir Med
. 2016 Sep;
4(11):902-910.
PMID: 27594440
Background: Antimicrobial resistance is a serious threat to public health, with most antibiotics prescribed in primary care. General practitioners (GPs) report defensive antibiotic prescribing to mitigate perceived risk of future...
10.
Jenkins A, Thomson A, Brown N, Semple Y, Sluman C, MacGowan A, et al.
J Antimicrob Chemother
. 2016 Aug;
71(10):2754-9.
PMID: 27494904
Objectives: The objectives of this study were to identify the amikacin dosage regimens and drug concentrations consistent with good outcomes and to determine the drug exposures related to nephrotoxicity and...